Figure 3.

Immune checkpoint inhibitors and stimulators in lymphoma. Numerous checkpoint inhibitors and stimulators are in clinical use or under investigation in lymphomas. Putative targets on T-cells (T), natural killer cells (NK), tumor-associated macrophages (M), and lymphoma cells (L) have been identified. Green shading and text denote stimulatory receptors and antibodies, respectively. Likewise, red shading and text denote checkpoint inhibitor proteins and antibodies, respectively.